➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Express Scripts
Baxter
Colorcon
McKinsey

Last Updated: November 29, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for tepotinib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug tepotinib?

tepotinib is an investigational drug.

There have been 10 clinical trials for tepotinib. The most recent clinical trial was a Phase 1 trial, which was initiated on September 4th 2020.

The most common disease conditions in clinical trials are Lung Neoplasms, Colorectal Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Merck KGaA, EMD Serono Research & Development Institute, Inc., and Merck KGaA, Darmstadt, Germany.

There are thirteen US patents protecting this investigational drug and one hundred and fifty-five international patents.

Recent Clinical Trials for tepotinib
TitleSponsorPhase
Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) AmplificationMerck KGaA, Darmstadt, GermanyPhase 2
Study of Tepotinib Combined With Cetuximab in Participants Left-Sided Metastatic Colorectal Cancer (mCRC) Acquired Resistance Due to Mesenchymal Epithelial Transition (MET) AmplificationEMD Serono Research & Development Institute, Inc.Phase 2
Bioequivalence of 5 Tablets of 100 Milligrams (mg) Versus 2 Tablets of 250 mg Tablet Formulation 3 (TF3) of TepotinibMerck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 1

See all tepotinib clinical trials

Clinical Trial Summary for tepotinib

Top disease conditions for tepotinib
Top clinical trial sponsors for tepotinib

See all tepotinib clinical trials

US Patents for tepotinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
tepotinib   Start Trial Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative MERCK PATENT GMBH (Darmstadt, DE)   Start Trial
tepotinib   Start Trial Pyrimidinyl pyridazinone derivatives Merck Patent Gesellschaft mit beschrankter Haftung (Darmstadt, DE)   Start Trial
tepotinib   Start Trial Pyridazinone derivatives Merck Patent GmbH (Darmstadt, DE)   Start Trial
tepotinib   Start Trial Pyridazinone derivatives MERCK PATENT GmbH (Darmstadt, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for tepotinib

Drugname Country Document Number Estimated Expiration Related US Patent
tepotinib Australia 2015360006 2034-12-11   Start Trial
tepotinib Brazil 112017010232 2034-12-11   Start Trial
tepotinib Canada 2970394 2034-12-11   Start Trial
tepotinib Chile 2017001477 2034-12-11   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Express Scripts
Baxter
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.